Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLBSNYSE:RM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLBSCaladrius Biosciences$6.37$0.38▼$1.24$26.05M0.91522,308 shs466,373 shsRMRegional Management$29.90-0.3%$30.38$25.41▼$37.52$296.64M1.2534,697 shs46,049 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLBSCaladrius Biosciences0.00%0.00%0.00%0.00%0.00%RMRegional Management+0.96%+5.33%+0.79%-15.96%+1.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLBSCaladrius BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ARMRegional Management4.0449 of 5 stars2.22.03.30.00.03.33.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLBSCaladrius Biosciences 0.00N/AN/AN/ARMRegional Management 2.33Hold$34.0013.71% UpsideCurrent Analyst Ratings BreakdownLatest GETB, TRB, CLBS, and RM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025RMRegional ManagementKeefe, Bruyette & WoodsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$33.00 ➝ $30.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLBSCaladrius BiosciencesN/AN/AN/AN/A$1.54 per shareN/ARMRegional Management$520.37M0.57$2.46 per share12.17$32.77 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLBSCaladrius Biosciences-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/ARMRegional Management$41.23M$3.307.194.59N/A7.01%13.20%2.54%7/30/2025 (Estimated)Latest GETB, TRB, CLBS, and RM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025RMRegional Management$0.67$0.70+$0.03$0.70$153.59 million$152.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLBSCaladrius BiosciencesN/AN/AN/AN/AN/ARMRegional Management$1.204.01%+8.10%36.36%N/ALatest GETB, TRB, CLBS, and RM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/1/2025RMRegional Managementquarterly$0.304.3%5/21/20255/21/20256/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLBSCaladrius BiosciencesN/A22.3322.33RMRegional Management3.9444.4244.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLBSCaladrius Biosciences15.57%RMRegional Management98.89%Insider OwnershipCompanyInsider OwnershipCLBSCaladrius Biosciences2.20%RMRegional Management10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLBSCaladrius Biosciences2760.58 million59.25 millionOptionableRMRegional Management1,9909.92 million9.10 millionOptionableGETB, TRB, CLBS, and RM HeadlinesRecent News About These CompaniesRegional Management (NYSE:RM) Downgraded to "Buy" Rating by StockNews.comMay 6, 2025 | marketbeat.comKeefe, Bruyette & Woods Has Lowered Expectations for Regional Management (NYSE:RM) Stock PriceMay 4, 2025 | americanbankingnews.comEarnings Update: Regional Management Corp. (NYSE:RM) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsMay 3, 2025 | finance.yahoo.comRegional Management Corp (RM) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ...May 1, 2025 | finance.yahoo.comQ1 2025 Regional Management Corp Earnings Call TranscriptMay 1, 2025 | gurufocus.comRegional Management Corp. (RM) Q1 2025 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comRegional Management (RM) Tops Q1 Earnings EstimatesApril 30, 2025 | zacks.comRegional Management Corp. Announces First Quarter 2025 ResultsApril 30, 2025 | finance.yahoo.comRegional Management (NYSE:RM) Stock Rating Upgraded by StockNews.comApril 28, 2025 | marketbeat.comRegional Management (RM) Projected to Post Earnings on WednesdayApril 25, 2025 | marketbeat.comAre Investors Undervaluing Regional Management (RM) Right Now?April 24, 2025 | zacks.com328,336 Shares in Regional Management Corp. (NYSE:RM) Purchased by Twin Lions Management LLCApril 24, 2025 | marketbeat.comRenaissance Technologies LLC Grows Holdings in Regional Management Corp. (NYSE:RM)April 21, 2025 | marketbeat.comRegional Management (NYSE:RM) Rating Lowered to "Buy" at StockNews.comApril 20, 2025 | marketbeat.comIs Regional Management (RM) Stock Undervalued Right Now?April 8, 2025 | zacks.comRegional Management Completes $265 Million SecuritizationApril 2, 2025 | tipranks.comRegional Management Corp. to Report First Quarter 2025 Results on Wednesday, April 30, 2025April 2, 2025 | businesswire.comRegional Management Corp. Completes $265 Million Asset-Backed SecuritizationApril 2, 2025 | businesswire.comRegional Management Updates Executive Compensation PlanMarch 19, 2025 | tipranks.comRegional Management Corp. Appoints Julie Booth to Its Board of DirectorsMarch 13, 2025 | gurufocus.comRegional Management Appoints Julie Booth to BoardMarch 13, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGETB, TRB, CLBS, and RM Company DescriptionsCaladrius Biosciences NASDAQ:CLBSCaladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Regional Management NYSE:RM$29.90 -0.08 (-0.27%) As of 03:33 PM EasternRegional Management Corp., a diversified consumer finance company, provides various installment loan products primarily to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders in the United States. It offers small and large installment loans; and retail loans to finance the purchase of furniture, appliances, and other retail products. The company also provides insurance products, including credit life, credit accident and health, credit property, vehicle single interest, and credit involuntary unemployment insurance; collateral protection insurance; and property insurance, as well as reinsurance products. In addition, its loans are sourced through branches, centrally-managed direct mail campaigns, and digital partners, as well as its consumer website. The company was incorporated in 1987 and is headquartered in Greer, South Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
